This study is a non-randomized, open-label, investigator-initiated safety and efficacy trial investigating the de-novo use of Eculizumab alongside conventional therapy to prevent antibody mediated rejection. The duration of the study will include an open enrollment period and at least 12 months of follow-up (post-transplant). The trial will enroll a total of 10 "sensitized" patients with a panel reactive antibody score greater than 70%, who are not previously or currently enrolled in another ongoing trial. The use of Eculizumab will be un-blinded to all study and research practitioner participants. A historical cohort of 10 additional patients will also be utilized for comparison.